Record Growth, Margin Debt: Can Q3 Deliver the Recovery?
SPR posted a 62% revenue blowout and 17% standalone organic growth. But gross margins compressed 400+ basis points to 55%-56%, and reported PAT was dragged down by ₹234 crore in Antolin finance costs. The real question: is Q3 margin normalization credible, or is this the new normal?
₹1,648 Cr
+62% YoY, +12% QoQ
₹162 Cr
+14% YoY
₹234 M
Q2 drag on PAT
+23% YoY
before finance costs
The headline reads like a blowout quarter. But the 62% topline sprint and 17% standalone organic growth sit alongside a margin compression that management is betting is temporary. On the call, SPR's MD was candid: Q2 gross margins fell 400+ basis points to 55%-56% from a ~60% baseline due to unrecovered commodity inflation (aluminum 2x, steel, copper, tools all elevated) hitting a 1-quarter lag on pass-through. Mix volatility added another 4-5% EBITDA drag. The good news is management expects normalization in Q3 as the commodity pass-through lag unwinds. The complication is that reported PAT is obscuring the underlying business health.
The PAT gap: what's temporary vs. structural
Reported PAT of ₹162 Cr (+14% YoY) lags the revenue growth significantly. The culprit: ₹234 crore in finance costs from Antolin acquisition debt in Q2 (₹486 Cr in H1). Peel this back and the picture shifts. Management's claimed organic PBT growth of +23% YoY — stated as 'PBT excluding Antolin finance costs' — is materially healthier than the +14% reported PAT headline. This is the distinction between reported (finance-cost-burdened) and organic (operating) profit. Once debt is repaid, PAT growth should re-accelerate.
The elevated finance costs by INR 234 million in Q2 FY27 and INR 486 million in H1 FY27 to fund the acquisition of the 3 Indian entities of Antolin had a temporary effect, which shall be normalised once the debt is repaid.
Management's claims: what holds up
Revenue growth 61% YoY to ₹1,674 Cr
₹1,648 Cr, +62% YoY
Supported
Gross margins compressed 400+ bps from ~60% baseline
Fell to 55%-56% as stated
Supported
EBITDA margin 17.9%
₹300 Cr EBITDA / ₹1,648 Cr revenue = 18.2%
Supported
Standalone EBITDA margin ~20%, 'best in industry'
19.9% in Q2 (110 bps below prior 21%)
Supported
Commodity pass-through lag to unwind Q3
Not yet validated; Q3 pending
On-track basis for now
New order pipeline ₹1,000+ Cr above ₹6,000 Cr base
Not independently verified; detail withheld for competitive reasons
Plausible but unverified
What changed on this call
Margin compression reset: gross margin fell 400+ bps, standalone EBITDA margin down 110 bps to 19.9%
Antolin integration confirmed on track operationally; finance costs ₹234M Q2 temporary, normalizing post-debt repayment
Capex guidance unchanged: still vague, management says numbers 'keep changing with every discussion'
Powertrain-agnostic portfolio reaffirmed at >35% of revenue; >60% of business insulated from powertrain shifts
New order wins ₹1,000+ Cr pipeline visible; ABS 2-wheeler supply begins April; precision plastics ramping
The bull-bear ledger
Record 62% YoY revenue growth; 17% standalone organic growth shows core franchise resilience
Powertrain-agnostic portfolio (>35%) and diversified adjacencies (ABS, lighting, precision molding) de-risk EV transition
New order pipeline ₹1,000+ Cr; Antolin adds high-growth interiors/lighting with lighter margin volatility
Qualified institutional placement ₹1,000 Cr completed; strong cash balance supports capex without dilution
Gross margin compression 400 bps is material; Q3 recovery not guaranteed if commodities stay elevated
Reported PAT growth only +14% vs. revenue +62%; organic profit healthier but recovery depends on finance cost normalization
Management evasive on capex numbers and customer order details; defensive posture signals execution or transparency risk
Operating at 75%-80% capacity; sudden volume spikes force product mix shifts that compressed margins 4-5%
Risks ranked by concern to a holder
Q3 EBITDA margin recovery fails to materialize
HighManagement's Q3 guidance on margin normalization is the core thesis validation. If gross margins stay at 55%-56% and commodity pass-through lag persists, compression becomes structural, not cyclical. Stock re-rates downside on multiple contraction.
Geopolitical commodity volatility persists; supply chains remain disrupted
HighAluminum 2x, steel/copper elevated due to Russia-Ukraine and Middle East tensions. If wars escalate or new disruptions emerge, commodity relief is delayed and pass-through lag extends into Q4, compressing margins another cycle.
Mix-driven margin volatility persists as capacity fills
MediumMix impact was 4-5% EBITDA drag in Q2 at 75%-80% utilization. If market volume normalizes or shifts to lower-margin products, margin recovery stalls even if commodities recover. Execution risk on product mix management.
Antolin debt repayment slower than expected; finance costs linger
Medium₹234 M Q2, ₹486 M H1 finance costs are temporary only if debt is repaid promptly. Delayed paydown extends PAT drag and signals capital allocation or refinancing risk.
Capex execution shortfall; expansions at Pithampur, Pathredi, Ghaziabad slip or overrun
MediumManagement refuses capex quantification. If expansions delay or cost more than budgeted, new order absorption and growth targets miss. Backlog might pivot to competitors.
Customer concentration; key customer or program delays or is lost
MediumManagement withholds order win details citing 'competitive sensitivity.' Suggests concentration risk. Loss of a major new order could crater 2-3 year growth trajectory.
Wage and regulatory cost step-up accelerates further
Low-MediumMinimum Wages Act revisions (Haryana, UP, Rajasthan) and PF/gratuity regulation changes already hit Q2. No further increases expected Q3, but structural cost floor is higher. Inflation risk if wage pressures return.
How the street is positioned
The stock sits at ₹4,302 as of Nov 5, down 11.13% from its all-time high of ₹4,841, but up 70.33% off the 52-week low of ₹2,526. It trades below its 20-day SMA (₹4,386) and 50-day SMA (₹4,467) but above the 200-day SMA (₹3,768), signaling a mid-trend pullback. RSI at 45 is neutral — neither oversold nor overbought. Volume trend is normal.
Ownership has shifted subtly but meaningfully. FII holdings rose 57 basis points QoQ to 8.21% (vs. 7.64% in Q4 FY26), showing institutional accumulation into the margin compression noise. DII holdings edged down 71 bps to 12.17%, suggesting marginal profit-taking by domestic funds. Promoter holdings remain stable at 43.75%. The FII buying is a vote of confidence that Q3 recovery is credible.
Bulk and block activity shows no insider concern. The only recent deal (Oct 21, 2026) was PI Opportunities AIF V buying ₹257 lakh shares at ₹4,490 from Prazim Trading — an institutional rotation, not insider selling. No promoter or management-linked selling near the highs. This is reassuring on conviction.
The market's read: price weakness is digesting margin shock, not rejecting the growth narrative. FII accumulation into the dip and lack of insider selling suggest the street believes Q3 recovery is credible. The 11% drawdown below ATH looks like opportunity pricing if Q3 validates normalization, and warning pricing if it doesn't.
What to watch next
1 · Q3 EBITDA margin recovery
The acid test. Management expects gross margins to recover from 55%-56% back toward 58%-60% as commodity pass-through lag unwinds. Standalone EBITDA margin should move back toward 20%+. If Q3 delivers, the narrative flips to 'Q2 was a dip' and PAT growth re-accelerates. If not, margin compression is structural and downside risks spike.
2 · Q3 PAT and finance cost trajectory
Reported PAT will still be dragged by Antolin finance costs, but the burden should ease as debt is repaid. Watch the absolute ₹ figure and YoY growth. If PAT growth returns to 15%+ YoY in Q3, organic health is confirmed and the stock has room to run. If it stays flat or negative, acquisition integration risk rises.
3 · Capex update and new order revenue timing
Management remains vague on capex, but Q3 should bring clarity on when Pithampur, Pathredi, Ghaziabad, Neemrana expansions come online. If management provides even a rough capex range, it reduces execution uncertainty. If the ₹1,000+ Cr new order pipeline starts shipping in Q4 or Q1, that validates topline visibility and extends growth momentum beyond FY27.
Shriram Pistons had a good quarter masked by temporary margin compression. The real story — 17% organic growth, +23% organic PBT growth, ₹1,000+ Cr new orders, powertrain-agnostic expansion — is intact. But the margin bet on Q3 recovery is not yet won. This is steady execution, not a step-change. The number to track from here is standalone EBITDA margin. If Q3 delivers a bounce back toward 20%, confidence returns and the stock re-rates upside on earnings credibility. If not, investors have a re-rating risk and should wait for clarity before adding. Hold on conviction of the long-term franchise; upgrade only on Q3 margin validation.
Informational and educational content only. Not investment advice.